A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs PF 06667272 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 01 Oct 2017 Status changed from recruiting to completed.
- 02 Sep 2017 Planned End Date changed from 31 Aug 2017 to 5 Sep 2017.
- 02 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 5 Sep 2017.